EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Efficacy and safety of elobixibat in patients with chronic constipation—A randomized, multicenter, double-blind, placebo-controlled, parallel-group study from India

Piyush Agarwal iD, Brajesh Kumar Jha, Jaganmohan Somagoni, Srinivas Shenoy B, Vipul Modh, Sanketh Kumar Chakilam, Vinay Kumar, Mukewar Shrikant Vasantrao, Mukesh Kalla, Anumula Kavitha, Omesh Goyal, Ashima Bhatia

Indian Journal of Gastroenterology · 2025-06 · 44 (3) · 336-344

DOI: 10.1007/s12664-024-01719-7 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Indian Journal of Gastroenterology, online erschienen am 22.02.2025. Verfasst von Piyush Agarwal und 11 weiteren Autor:innen. Beteiligte Einrichtung: Global Clinical Management, Dr. Reddy's Laboratories Pvt. Ltd, Hyderabad, 500 016, India. piyushagarwal@drreddys.com. Hauptthemen laut MEDLINE: Constipation, Thiazepines, Gastrointestinal Agents, Citrates. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dr. Reddy's Laboratories.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Elobixibat is a locally acting ileal bile acid transporter (IBAT) inhibitor that relieves functional constipation in patients by accelerating colonic transit. In this study, we aimed at determining the efficacy and safety of elobixibat for short-term treatment (two weeks) of chronic constipation in Indian patients.

Methods

The present study was a randomized, double-blind, parallel-group, placebo-controlled, phase III study to evaluate efficacy and safety of elobixibat. The study planned to enroll patients with chronic constipation of at least six months' duration, satisfying Rome IV criteria for functional constipation. Following a run-in of approximately 14 days to confirm eligibility and determine baseline frequency of spontaneous bowel movements (SBMs), eligible patients were randomized 1:1 either to elobixibat or to placebo groups. The change in weekly frequency of spontaneous bowel movements (SBMs) at the end of treatment (week two) over baseline was the primary efficacy endpoint in this trial. Primary efficacy analyses were based on the modified intention-to-treat (mITT) population. This trial is registered at CTRI (Clinical Trial Registry of India).

Results

Between April 2023 and December 2023, 150 patients were randomized into the two-week trial. In mITT population ( n = 146 [elobixibat = 75 and placebo = 71]), the least square mean (LSM) difference between elobixibat (3.83) and placebo (2.68) was 1.15 (95% CI, 0.31, 1.99) demonstrating a statistically significant improvement ( p = 0.008) in weekly frequency of SBMs (week two over baseline) with the use of elobixibat. The proportions of patients with a complete spontaneous bowel movement (CSBM) “response” was significantly higher with elobixibat (49.33%) compared to the placebo (26.76%) treatment (difference 22.57% [95% CI, 8.36%, 36.78%] [ p = 0.005]). The most common adverse event (AE) was abdominal pain (elobixibat = 6 patients [7.89%] vs. placebo = 3 patients [4.05%]).

Conclusions

Elobixibat was well tolerated and improved bowel movement frequency within two weeks of treatment in Indian patient population with chronic constipation. Clinical trial registry number CTRI/2022/10/046690 Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ConstipationThiazepinesGastrointestinal AgentsCitratesHumansDouble-Blind MethodMaleFemaleChronic DiseaseIndiaAdultTreatment OutcomeMiddle AgedDefecationYoung AdultDipeptides

Stichwörter der Autor:innen

Bile acid binding proteinConstipationDefecationElobixibatIntention to treat analysis

Substanzen

elobixibatThiazepinesGastrointestinal AgentsCitratesDipeptides

Autor:innen und Institutionen

  • Global Clinical Management, Dr. Reddy's Laboratories Pvt. Ltd, Hyderabad, 500 016, India. piyushagarwal@drreddys.com.
  • Global Clinical Management, Dr. Reddy's Laboratories Pvt. Ltd, Hyderabad, 500 016, India.
  • GSVM Medical College, Kanpur, 208 002, India.
  • Midas Multispecialty Hospital Pvt. Ltd, Nagpur, 440 010, India.
  • S.R. Kalla Memorial Gastro and General Hospital, Jaipur, 302 006, India.
  • Government General Hospital, Guntur, 522 001, India.

ORCID-Profile: Piyush Agarwal

Förderung

  • Dr. Reddy's Laboratories

Zitieren

APA

Agarwal, P., Jha, B. K., Somagoni, J., B, S. S., Modh, V., Chakilam, S. K., Kumar, V., Vasantrao, M. S., Kalla, M., Kavitha, A., Goyal, O., & Bhatia, A. (2025). Efficacy and safety of elobixibat in patients with chronic constipation—A randomized, multicenter, double-blind, placebo-controlled, parallel-group study from India. Indian Journal of Gastroenterology, 44(3), 336-344. https://doi.org/10.1007/s12664-024-01719-7

Vancouver

Agarwal P, Jha BK, Somagoni J, B SS, Modh V, Chakilam SK, et al. Efficacy and safety of elobixibat in patients with chronic constipation—A randomized, multicenter, double-blind, placebo-controlled, parallel-group study from India. Indian Journal of Gastroenterology. 2025;44(3):336-344. doi:10.1007/s12664-024-01719-7

BibTeX
@article{Agarwal2025,
  author = {Agarwal, Piyush and Jha, Brajesh Kumar and Somagoni, Jaganmohan and B, Srinivas Shenoy and Modh, Vipul and Chakilam, Sanketh Kumar and Kumar, Vinay and Vasantrao, Mukewar Shrikant and Kalla, Mukesh and Kavitha, Anumula and Goyal, Omesh and Bhatia, Ashima},
  title = {Efficacy and safety of elobixibat in patients with chronic constipation—A randomized, multicenter, double-blind, placebo-controlled, parallel-group study from India},
  journal = {Indian Journal of Gastroenterology},
  year = {2025},
  volume = {44},
  number = {3},
  pages = {336--344},
  doi = {10.1007/s12664-024-01719-7}
}
Kostenlos starten →